Literature DB >> 29960957

Phytobezoar and duodenal ulcer as complication of Duodopa therapy in a patient affected by Parkinson's disease.

Paolo Cerrone1,2, Michele Marchese3, Maria Antonietta Pistoia1,3, Carmine Marini2,4.   

Abstract

Continuous duodenal infusion of levodopa/carbidopa intestinal gel (LCIG) is an established treatment to control motor fluctuations in Parkinson's disease. Duodenal infusion allows a steady absorption of the drug in the small bowel, reducing plasmatic fluctuations of levodopa. Some complications may occur during the treatment, often related to intrajejunal percutaneous endoscopic gastrostomy (PEG-J). We report a case of duodenal ulcer associated with a phytobezoar involving the end of jejunal probe, in a patient who underwent PEG-J for LCIG infusion. In the last 2 weeks, the patient suffered from abdominal pain and dyspepsia. Oesophagogastroduodenoscopy showed an ulcerative lesion of the duodenum due to traction of the jejunal tube; the end of the jejunal tube was wrapped in a phytobezoar. This case is interesting because of the extension of the ulcerative lesion due to PEG-J dislocation and because of the subtle symptoms associated with it. © BMJ Publishing Group Limited [year]. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  drugs: gastrointestinal system; endoscopy; parkinson’s disease

Mesh:

Substances:

Year:  2018        PMID: 29960957      PMCID: PMC6040509          DOI: 10.1136/bcr-2017-223884

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  23 in total

1.  Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.

Authors:  D Nyholm; A I M Nilsson Remahl; N Dizdar; R Constantinescu; B Holmberg; R Jansson; S-M Aquilonius; H Askmark
Journal:  Neurology       Date:  2005-01-25       Impact factor: 9.910

2.  Gastric bezoar complication of Duodopa(®) therapy in Parkinson's disease, treated with Coca-Cola(®).

Authors:  Pantelis Stathis; Vasilios Tzias; Pavlos Argyris; Georgia Barla; Maria Maltezou
Journal:  Mov Disord       Date:  2014-06-07       Impact factor: 10.338

Review 3.  Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.

Authors:  Johan Virhammar; Dag Nyholm
Journal:  Ther Adv Neurol Disord       Date:  2016-12-01       Impact factor: 6.570

4.  Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.

Authors:  Angelo Antonini; Ashley Yegin; Cornelia Preda; Lars Bergmann; Werner Poewe
Journal:  Parkinsonism Relat Disord       Date:  2014-12-19       Impact factor: 4.891

5.  Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.

Authors:  Florence C F Chang; Vu Kwan; David van der Poorten; Neil Mahant; Nigel Wolfe; Ainhi D Ha; Jane M Griffith; David Tsui; Samuel D Kim; Victor S C Fung
Journal:  J Clin Neurosci       Date:  2016-01-14       Impact factor: 1.961

6.  Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion.

Authors:  Tommaso Martino; Donato Melchionda; Paolo Tonti; Vincenzo De Francesco; Alessandra Lalla; Luigi Maria Specchio; Carlo Avolio
Journal:  J Neural Transm (Vienna)       Date:  2016-09-10       Impact factor: 3.575

7.  Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.

Authors:  Angelo Antonini; Ioannis U Isaias; Margherita Canesi; Maurizio Zibetti; Francesca Mancini; Luigi Manfredi; Marco Dal Fante; Leonardo Lopiano; Gianni Pezzoli
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

Review 8.  The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease.

Authors:  Dag Nyholm
Journal:  Parkinsonism Relat Disord       Date:  2007-08-17       Impact factor: 4.891

9.  Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.

Authors:  A Antonini; F Mancini; M Canesi; R Zangaglia; I U Isaias; L Manfredi; C Pacchetti; M Zibetti; F Natuzzi; L Lopiano; G Nappi; G Pezzoli
Journal:  Neurodegener Dis       Date:  2008-03-06       Impact factor: 2.977

10.  Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.

Authors:  Hubert H Fernandez; David G Standaert; Robert A Hauser; Anthony E Lang; Victor S C Fung; Fabian Klostermann; Mark F Lew; Per Odin; Malcolm Steiger; Eduard Z Yakupov; Sylvain Chouinard; Oksana Suchowersky; Jordan Dubow; Coleen M Hall; Krai Chatamra; Weining Z Robieson; Janet A Benesh; Alberto J Espay
Journal:  Mov Disord       Date:  2014-12-24       Impact factor: 10.338

View more
  2 in total

1.  PEG-J replacement for duodenal levodopa infusion in Parkinson's disease patients: a retrospective study.

Authors:  Simone Simoni; Pasquale Nigro; Marta Filidei; Giulia Cappelletti; Federico Paolini Paoletti; Danilo Castellani; Mirko Gaggiotti; Lucilla Parnetti; Nicola Tambasco
Journal:  BMC Neurol       Date:  2022-01-13       Impact factor: 2.474

2.  A knotty problem: phytobezoar and small bowel occlusion as a complication of a gastro-jejunal catheter for continuous Duodopa infusion: a case report.

Authors:  Todor Ivanov; Ingrid Perlot; Laura Romero Stoca; Catherine Deleuze; Celine Rasmont; Jean Lemaitre
Journal:  J Surg Case Rep       Date:  2022-03-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.